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Moraxella catarrhalis is a human-specific commensal of the respiratory tract and an
opportunistic pathogen. It is one of the leading cause of otitis media in children and of
acute exacerbations in patients with chronic obstructive pulmonary disease, resulting
in significant morbidity and economic burden. Vaccines and new immunotherapeutic
strategies to treat this emerging pathogen are needed. Complement is a key component
of innate immunity that mediates the detection, response, and subsequent elimination of
invading pathogens. Many pathogens including M. catarrhalis have evolved complement
evasion mechanisms, which include the binding of human complement inhibitors such
as C4b-binding protein (C4BP) and Factor H (FH). Inhibiting C4BP and FH acquisition
by M. catarrhalis may provide a novel therapeutic avenue to treat infections. To achieve
this, we created two chimeric proteins that combined the Moraxella-binding domains
of C4BP and FH fused to human immunoglobulin Fcs: C4BP domains 1 and 2 and
FH domains 6 and 7 fused to IgM and IgG Fc, respectively. As expected, FH6-7/IgG
displaced FH from the bacterial surface while simultaneously activating complement
via Fc-C1q interactions, together increasing pathogen elimination. C4BP1-2/IgM also
increased serum killing of the bacteria through enhanced complement deposition, but
did not displace C4BP from the surface of M. catarrhalis. These Fc fusion proteins could
act as anti-infective immunotherapies. Many microbes bind the complement inhibitors
C4BP and FH through the same domains as M. catarrhalis, therefore these Fc fusion
proteins may be promising candidates as adjunctive therapy against many different
drug-resistant pathogens.
Keywords: pathogen, Moraxella catarrhalis, fusion proteins, complement, antibacterial
INTRODUCTION
Moraxella catarrhalis is a Gram-negative diplococcus which commonly colonizes the
nasopharyngeal cavity of humans asymptomatically (1). However, in recent years, a greater
appreciation of the virulent nature of this bacterium has emerged and M. catarrhalis is now
considered an opportunistic pathogen (1, 2). M. catarrhalis is the third most common cause of
Abbreviations: AF, Alexa Fluor; BHI, brain-heart infusion; BSA, bovine serum albumin; C4BP, C4-binding protein; CCP,
complement control protein; CFSE, carboxyfluorescein succinimidyl ester; CFU, colony forming unit; CHO, Chinese hamster
ovary; FH, factor H; gMFI, geometric mean fluorescence intensity; GVB, gelatin veronal buffer; Ig, immunoglobulin; MAC,
membrane attack complex; NHS, normal human serum; OD, optical density; Usp, ubiquitous surface protein; WT, wild-type.
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acute sinusitis and otitis media in children and is responsible for a
variety of lower respiratory tract infections in immunocompetent
hosts and patients with chronic lung disease (2, 3). Rarely,
M. catarrhalis can cause bacteraemia and pneumonia in
immunocompromised individuals (4).
Humans have evolved a variety of mechanisms to evade
infections caused by a multitude of microbial pathogens. The
complement system represents an effective arm of innate
immunity involved in detecting, labeling and eradicating
potential microbial threats. Bacterial activation of complement
is mediated by specific recognition molecules, which bind
to conserved structures on the bacterial surface, initiating
an enzymatic cascade resulting in the formation of the C3
convertases and cleavage of C3, the central protein of the
complement cascade (5, 6). A strong activator of the classical
pathway is the recognition subunit of the C1 complex, C1q
(7). C1q interacts with high avidity with the Fc region of
clustered immunoglobulin (Ig)Gs or multivalent IgM molecules
and in conjunction with serine proteases, C1r and C1s, initiates
proteolytic events resulting in C3 convertase formation (7). C3
can be cleaved into multiple fragments with opsonic properties
and when deposited on the microbial surface, can interact with
complement receptors expressed on the surface of professional
phagocytes culminating in uptake and destruction of the
pathogen (8). Further activation and processing of C3 forms C5
convertases, that cleave C5 into C5a, a potent chemoattractant,
and C5b, an essential building block of the membrane attack
complex (MAC). Interaction of C5b with complement proteins
C6 through C9 results in formation and insertion of MAC leading
to a reduction in membrane potential and bacterial lysis of
Gram-negative bacteria (5, 6).
To prevent complement destruction of host cells, a suite
of soluble and cell surface regulators maintain complement
homeostasis (9). Two soluble proteins, Factor H (FH) and C4b-
binding protein (C4BP) are pivotal for preventing unwanted
complement activation, both exerting their influence at the level
of C3 convertase inhibition (9–11). FH is the major soluble
inhibitor of the alternative pathway (AP), binds to C3b via
complement control protein (CCP) domains 1–4 and accelerates
the decay of the alternative C3 convertase while also acting as a
cofactor for the serine protease, factor I mediated inactivation
of C3b (9, 10). C4BP is the major inhibitor of the classical and
lectin pathways, interacting with and limiting the function of
complement protein C4b (9, 11). In similar fashion to FH, C4BP
acts as a cofactor for both FI proteolysis of cell-bound and soluble
C4b, disrupting formation of the classical C3 convertase (9, 11)
and fluid phase C3b inhibiting AP activity (12). Furthermore,
C4BP can accelerate the decay of formed classical pathway C3
convertase (11).
The success of any disease-causing organism depends on
its ability to resist host immunity (13–15). As FH and
C4BP are soluble proteins, a wide variety of pathogens have
evolved mechanisms to bind and recruit these proteins to their
surface, thus disrupting complement deposition (13, 16). Most
bacteria recruit FH through CCP domains 6–7 and 18–20,
thereby permitting FH domains 1–4 to inhibit complement
(10, 15). Pathogen binding of C4BP is generally associated with
CCP1-3, which is also responsible for C4b and C3b binding
(11, 15). However, C4BP is a multimeric protein with seven
identical alpha chains, which permits its simultaneous binding
to different ligands while maintaining complement inhibitory
activity (11, 15).
Infections are primarily curtailed by antibiotics or vaccines.
In recent years, antibiotic resistance has become a major health
problem globally, with the proliferation of multidrug-resistant
bacteria (17). Development of new antibiotics and vaccines
does not appear to meet the current medical demand, therefore
new antimicrobial approaches are urgently needed. Chimeric
proteins that fuse pathogen binding domains of either FH
(CCPs 6–7) of the Fc region of human IgG (FH6–7/IgG) or
C4BP (CCPs 1–2) fused to the constant domains CH2, CH3,
and CH4 of IgM (C4BP1–2/IgM) resulting in a hexavalent
chimeric protein have been developed as alternative strategies
to control infection (18, 19). The net result is displacement
of complement inhibitors from the bacterial surface with
simultaneous complement activation via Fc-C1q interaction,
which increases pathogen elimination. This approach has shown
promise in enhancing killing of Non-typeable Haemophilus
influenzae (NTHi) (20), Neisseria meningitidis (18), Neisseria
gonorrhoeae (19, 21), and Streptococcus pyogenes (22). In this
study we tested the bactericidal activity of both fusion proteins
against M. catarrhalis.
MATERIALS AND METHODS
Bacteria and Cell Line Culture Conditions
Bacteria used in this study were M. catarrhalis strain RH4 (23),
isogenic mutants of RH4 devoid of UspA1 (1uspA1), UspA2
(1uspA2), and both UspA1 and UspA2 (1uspA11uspA2) (24),
and clinical isolates KR473, KR478, KR479, KR485, KR502,
KR507, KR508, KR530, KR533, KR488, KR504, KR506, KR531,
KR539, KR540, KR477, KR480, KR482, KR510, KR515, and
KR527 (25). All strains of M. catarrhalis were routinely cultured
on chocolate blood agar and grown overnight at 37◦C with
5% CO2. Prior to experiments, bacteria were sub-cultured
from overnight plates and streaked onto new chocolate blood
agar plates and grown for 6–8 h. Bacteria were scraped from
plates and resuspended into freezing medium [25% brain-heart
infusion (BHI)/glycerol], and subsequently aliquoted and stored
at−80◦C until use.
Staphylococcus aureus strain USA300 JE2 were grown in
tryptic soy broth at 37◦C with shaking (200 rpm). Overnight
cultures were normalized to an OD600 nm = 0.1 in fresh medium
and grown under the same conditions until an OD600 nm = 0.3–
0.4, corresponding to mid-exponential phase of growth. Bacteria
were centrifuged and washed once in sterile PBS and normalized
to an OD600 nm = 1 which equates to 1–2× 108 CFU/ml.
FreeStyle Chinese hamster ovary (CHO) S suspension cells
(Life Technologies), grown in FreeStyle CHO expression medium
supplemented with 8 mM L-glutamine were used for the
expression of FH6-7/IgG fusion protein as described (22). Cell
cultures were grown in 250 ml Erlenmeyer flasks at 37◦C with
8% CO2 with shaking (130 rpm). Adherent CHO cells grown
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in serum-free OptiMEM Glutamax medium were used for the
expression of C4BP1-2/IgM as described (19). For expression and
collection of C4BP1-2/IgM fusion protein, adherent cells were
washed twice in PBS and grown in Opti-MEM for 48 h. Following
48 h, cells were washed and grown in CHO expression medium
for 24 h and this procedure repeated for 15 days.
Purification of Fusion Proteins
Fusion protein FH6-7/IgG were expressed in CHO cells and
purified on protein A/G columns as described previously (22).
Bound proteins were eluted using 0.1M glycine, pH = 2.7.
Protein eluate was dialyzed three time in PBS at 4◦C and protein
concentrations calculated on aBio photomoter. The C4BP1-
2/IgM fusion protein was purified using a HiTrap Normal human
serum (NHS)-activated Sepharose 5 ml column coupled with
antibody MK104, which recognizes the CCP-1 domain of C4BP
as described previously (19).
Binding of Fusion Proteins to
M. catarrhalis
Moraxella catarrhalis glycerol stocks were thawed at 37◦C for
30 min and washed once in PBS for 5 min at 5000 × g.
Bacteria were normalized to OD600 nm of 1, stained with
carboxyfluorescein succinimidyl ester (CFSE, 10 µM) for 30 min
at 37◦C and washed once in PBS, for gating in flow cytometry
assays. Bacterial concentrations were adjusted to an OD600 nm of
0.5 in PBS and thereafter 50 µl was mixed with 50 µl of increasing
concentrations of fusion proteins for 30 min at 37◦C in a covered
V-bottomed 96 well plate. Bacteria were centrifuged for 5 min at
5000× g at room temperature (RT) and washed once in PBS. To
detect FH6-7/IgG binding to M. catarrhalis, bacteria were stained
with Alexa Fluor (AF) – 488 goat anti-human IgG (1:1000;
Invitrogen) in 1% (w/v) BSA/PBS for 30 min at RT. To detect
C4BP1-2/IgM binding, bacteria were stained with polyclonal
rabbit anti-human IgM (1:1000; Dako) for 30 min at RT. Bacteria
were centrifuged and washed once in 1% (w/v) BSA/PBS and
for C4BP1-2/IgM detection, followed by a secondary antibody
staining (AF-647 goat anti-rabbit, 1:1000; Invitrogen) for 30 min
in the dark. For both fusion proteins, following Ab staining,
bacteria were centrifuged and washed once in 1% (w/v) BSA/PBS,
resuspended in 150 µl PBS and deposited fusion proteins were
assessed using a CytoFLEX flow cytometer. Bacteria incubated
without fusion protein was used as a negative control. CFSE-
stained and non-stained bacteria were used for gating purposes
and a minimum of 20,000 events were examined. To assess the
binding of C4BP-IgM in the presence of serum, the fusion protein
was labeled with AF 488 using AF 488 microscale labeling kit
(A10235, Molecular Probes).
Serum Bactericidal Assays
Bacteria were prepared as described in bacteria-fusion protein
binding section, with the omission of the CFSE staining. NHS
was prepared from freshly drawn blood with informed consent
from at least eight healthy volunteers as described (26) and in
accordance with the recommendations of the ethical committee
at Lund University (Permit 2017/582) and the Declaration of
Helsinki (27). Bacteria were normalized to OD600 nm of 0.05.
Fifty microliters of bacteria were incubated in the presence or
absence of 40 µl of fusion protein (final concentration 50 µg/ml)
for 30 min at 37◦C in GVB++ buffer [5 mM veronal buffer
pH 7.3, 0.1% (w/v) gelatin, 140 mM NaCl, 1 mM MgCl2,
and 0.15 mM CaCl2]. After 30 min, 10 µl of pooled NHS was
added and incubated with bacteria for a further 30 min at 37◦C.
Alternatively, bacteria and fusion protein in GVB++ buffer (0–
100 µg/ml) in addition to serum were added simultaneously and
incubated for 30 min at 37◦C. For calculation of bacteria survival,
samples of bacteria were removed at time 0 and time 30 min
following incubation at 37◦C, serially diluted in PBS and spread
onto chocolate agar plates for colony enumeration after growth
overnight at 37◦C with 5% CO2. As a control heat-inactivated
serum was used following treatment at 56◦C for 30 min.
Binding Competition Experiments
Bacteria were thawed, washed once in PBS and normalized to
an OD600 nm of 0.5. Two experimental protocols were utilized:
(1) Bacteria were pre-incubated with varying concentrations of
either FH6–7/IgG or C4BP1–2/IgM in GVB++ buffer for 30 min
at 37◦C. Following incubation, NHS treated with the complement
C5 inhibitor OmCI (10 µg/ml; 0.625 µM) (expression vector
obtained from Swedish Orphan Biovitrum) (28) on ice for 30 min
was added to a final concentration of 10% and incubated at
37◦C for 30 min; (2) Bacteria, FH6-7/IgG fusion protein (at a
final concentration of 0, 50, or 100 µg/ml) and OmCI-treated
NHS (final concentration of 10%) were added simultaneously
and incubated at 37◦C for 30 min. Following incubation, bacteria
were centrifuged and washed once in 1% (w/v) BSA/PBS. To
determine serum FH binding, biotinylated Ab specific to CCP
domain 5 of FH (MRC OX-24-biotin; 1:500) was used for
30 min at RT. Bacteria were washed once in 1% (w/v) BSA/PBS
and stained with AF647-streptavidin (1:1000; Invitrogen) in the
dark for 30 min at RT. To determine serum C4BP binding,
Ab specific to CCP domain 4 of the alpha chains of C4BP
(MK67; 1:1000) (29) was used for 30 min at RT. Bacteria were
washed once in 1% (w/v) BSA/PBS and stained with AF-647
goat anti-mouse (1:1000; Invitrogen). Bacteria were centrifuged
and washed once in 1% (w/v) BSA/PBS, resuspended in 150 µl
PBS and serum FH or C4BP binding were assessed using a
CytoFLEX flow cytometer.
Complement Deposition Assays
Bacteria were prepared as described in the binding assay
section. For detection of complement components C3d and
iC3b, bacteria, fusion protein, and OmCI-treated NHS (final
concentration of 5%) were incubated for 30 min at 37◦C. Bacteria
were centrifuged and washed once in PBS and stained with either
a monoclonal murine anti-human C3d Ab (1:1000, Quidel, A207)
or a monoclonal murine anti-human iC3b Ab (1:1000, Quidel,
A209) in 1% (w/v) BSA/PBS for 30 min at RT. For detection of
MAC, NHS at a final concentration of 10% was used and bacteria
incubated for 20 min at 37◦C. Following washing, bacteria
were stained with monoclonal mouse anti-human C9 neoantigen
(1:1000, Hycult, aE11) for 30 min at RT. Bacteria were centrifuged
and washed once in PBS followed by staining with AF-647 goat
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anti-mouse, 1:1000; Invitrogen) for 30 min in the dark at RT.
Bacteria were centrifuged and washed once in PBS, resuspended
in 150 µl of PBS and deposited complement components detected
using a CytoFLEX flow cytometer (Beckman Coulter).
Whole Blood Survival and Phagocytosis
Assay
Moraxella catarrhalis were prepared as described in the binding
assay section. S. aureus were grown as described on the bacteria
section. Bacteria were normalized to OD600 nm of 1, stained with
CFSE (10 µM) for 30 min at 37◦C and washed once in PBS.
Human blood was taken from healthy volunteers and treated
with lepirudin (Refludan 50 µg/ml; Celgene). Five hundred
microliters of blood were incubated for 30 min with 1 µM
OmCI, 10 µM cytochalasin D (Sigma-Aldrich) or both, on
an end-over-end shaker at 37◦C and 5% CO2. Approximately
5 × 105 CFU of CFSE-stained bacteria were added to blood,
and blood suspensions were incubated on a shaker at 37◦C
and 5% CO2.
To assess the survival of bacteria in blood, at specific time
points a sample of the suspension was collected, serially diluted
in PBS and plated onto chocolate agar plates (M. catarrhalis)
or blood agar plates (S. aureus). Agar plates were incubated
overnight at 37◦C and 5% CO2 and CFU/mL determined
following enumeration of surviving bacteria.
To assess the phagocytosis of bacteria, at specific time
points a sample of the suspension was collected, red blood
cells lysis was performed by addition of water followed by
addition of 10× PBS to restore osmotic pressure. Cells were
centrifuged at 300 g for 5 min and fixed by incubation in 4%
paraformaldehyde in PBS for 15 min at RT. Cells were stained
with anti-CD14 APC antibody (Beckman Coulter) for 30 min,
washed once in PBS and resuspended in PBS for analysis using
a CytoFLEX flow cytometer.
Statistical Analysis
To examine differences between experimental groups, a one-way
or two-way ANOVA was used (GraphPad Prism v7.0); a p-value
was <0.05 was considered statistically significant. The p-values
shown in figure legends represent the post hoc tests.
RESULTS
Fusion Proteins Bind to M. catarrhalis
The fusion protein FH6–7/IgG was created by combining the
CCP6 and CCP7 domains of FH with the Fc region of human
IgG (Figure 1A). C4BP1–2/IgM was made by fusing the CCP1
and CCP2 domains of C4BP together with the constant domains
CH2, CH3, and CH4 of human IgM (Figure 1B). C4BP1–2/IgM
forms multimers similarly to IgM, hexamers (dodecamers of
C4BP CCPs 1–2; ∼80%) or pentamers (decamers of C4BP CCPs
1–2;∼20%) (19).
To understand whether fusion proteins (FH6–7/IgG and
C4BP1–2/IgM) could be used as alternative treatment strategies,
we first explored whether these proteins could bind the well-
characterized M. catarrhalis strain RH4. M. catarrhalis is known
to bind both soluble complement inhibitors, FH and C4BP
(24, 30). Fusion proteins incubated with bacteria over a range
of concentrations confirmed that M. catarrhalis interacts with
FH6–7/IgG (Figure 1C) and C4BP1–2/IgM (Figure 1D) in a
dose-dependent fashion.
The ubiquitous surface proteins (Usp) A1 and A2 are high-
molecular weight proteins that are abundantly expressed at the
surface of M. catarrhalis (31). UspA2 plays an important role
in immunity evasion as it can bind the complement inhibitors
C4BP (24), vitronectin (32) and plasminogen (33). To test the
possibility that the fusion proteins bind M. catarrhalis through
UspA1 and/or UspA2, we used mutants lacking UspA1 and/or
UspA2. The binding of FH6–7/IgG was reduced in the single
mutant 1uspA2 and the double mutant 1uspA11uspA2, but not
in 1uspA1, compared to the wild-type (WT) strain (Figure 1E).
A similar observation was made when assessing the binding
of whole FH (Figure 1G), suggesting that the fusion protein
FH6–7/IgG, like FH, binds partly through UspA2. The binding
of C4BP1–2/IgM was unchanged in 1uspA1 compared to WT
M. catarrhalis, but almost completely abrogated in 1uspA2 and
1uspA11uspA2 (Figure 1F), similar to the binding of C4BP from
NHS (Figure 1H). Therefore, the fusion protein C4BP1–2/IgM
binds M. catarrhalis mainly through UspA2.
FH6–7/IgG but Not C4BP1–2/IgM
Prevents Binding and Outcompetes
Respective Soluble Complement
Inhibitor
We investigated the interplay between fusion proteins and the
ability of M. catarrhalis to recruit FH and C4BP to the bacterial
surface. Firstly, we pre-incubated M. catarrhalis strain RH4
with increasing concentrations of FH6–7/IgG or C4BP1–2/IgM
followed by the addition of OmCI-treated serum as a source of
FH and C4BP. After incubation we examined the amount of
FH or C4BP binding with antibodies specific to CCP domains
present in serum-derived FH and C4BP, but not in the respective
Fc fusion proteins. Preincubation of RH4 with FH6–7/IgG with
concentrations as low as 1.5 µg/ml resulted in a significant
reduction in FH binding from serum with an inverse correlation
between FH6–7/IgG and FH binding continuing in a dose-
dependent fashion (Figure 2A). Next, we assessed whether FH6–
7/IgG could outcompete serum FH in binding to M. catarrhalis
when added concurrently with NHS. Under these experimental
settings, FH6–7/IgG also outcompeted FH binding from serum
(Figure 2B). In contrast, no difference was observed in serum
C4BP binding when bacteria were pre-incubated with increasing
concentrations of C4BP1–2/IgM (Figure 2C). These data show
that FH6–7/IgG can successfully displace FH at the surface of
M. catarrhalis, while C4BP1–2/IgM does not out-compete serum
C4BP, suggesting that C4BP binds the bacteria with a higher
affinity than the fusion protein. Based on the observation that
C4BP-IgM does not outcompete C4BP for binding to the bacteria,
we tested whether C4BP-IgM could bind bacteria in the presence
of serum (OmCI-treated). We found that the binding of C4BP-
IgM is decreased when increasing concentrations of serum are
added at the same time (Figure 2D), but there seems to be still
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FIGURE 1 | FH 6-7/IgG and C4BP1-2/IgM bind to M. catarrhalis. (A,B) Schematic representation of fusion proteins FH6-7/IgG and C4BP1-2/IgM, respectively.
(C) Binding of FH6-7/IgG and (D) C4BP1-2/IgM to M. catarrhalis RH4 [wild-type (WT) reference strain] assessed by flow cytometry. (E–H) Binding of RH4 WT and
isogenic mutants lacking uspA1 and/or uspA2 to (E) FH6-7/IgG, (F) C4BP1-2/IgM, (G) factor H (FH), and (F) C4b-binding protein (C4BP). Mean (±SD) from three
independent experiments are shown. Statistical significance of differences was calculated using one-way ANOVA with Dunnett’s post-test (E–H); **p < 0.01 and
****p < 0.0001.
Frontiers in Immunology | www.frontiersin.org 5 September 2020 | Volume 11 | Article 2122
fimmu-11-02122 August 30, 2020 Time: 10:11 # 6
Laabei et al. Fusion Proteins Enhance Moraxella Killing
FIGURE 2 | FH6-7/IgG competes out serum FH, but C4BP1-2/IgM does not compete out serum C4BP. (A) M. catarrhalis were pre-incubated in increasing amounts
of FH6-7/IgG, followed by the addition of OmCI-treated serum (C5-inhibitor). The binding of FH from NHS was assessed by flow cytometry using antibodies specific
to domains present in serum derived FH but absent on the fusion proteins. (B) FH6-7/IgG and NHS were added simultaneously to the bacteria and binding of FH
from NHS was assessed. (C) M. catarrhalis pre-incubated in increasing amounts of C4BP1-2/IgM, followed by OmCI-treated serum were tested for the binding of
C4BP from NHS by flow cytometry using antibodies specific to domains present in serum derived C4BP but absent on the fusion proteins. (D) Alexa Fluor
488-labeled C4BP-IgM was added simultaneously with differing concentrations of OmCI-treated serum to bacteria to assess the binding of the fusion protein. Mean
(±SD) from three independent experiments are shown. Statistical significance of differences was calculated using one-way ANOVA with Dunnett’s post-test;
***p < 0.001 and ****p < 0.0001.
a significant binding in the presence of 10% NHS which is the
amount used in serum bactericidal assays.
Serum Bactericidal Activity Is Enhanced
by Fusion Proteins
Complement activation results in phagocytic clearance of
bacteria as well as direct bacterial killing through the formation
of lytic MAC. Gram-positive bacteria are not sensitive to
MAC-mediated killing, but it plays a critical role against
Gram-negative bacteria such as M. catarrhalis (34). In order
to assess the respective roles of phagocytosis and MAC-
mediated killing in clearance of M. catarrhalis, we employed a
whole blood infection model, using human blood pre-treated
with complement C5 inhibitor OmCI, phagocytosis inhibitor
cytochalasin D or both. We observed that M. catarrhalis
survival in whole blood is increased when complement is
inhibited but not significantly changed when phagocytosis was
inhibited (Figure 3A). However, phagocytosis of M. catarrhalis
by granulocytes and monocytes remained unchanged by OmCI
compared to untreated blood, while cytochalasin D inhibited
phagocytosis as expected (Figure 3B). It is worth noting that this
method does not distinguish between live and dead bacteria being
taken up by phagocytes. This confirms that phagocytosis does
not play a major role in M. catarrhalis killing in whole blood
as it does not correlate with bacteria survival numbers: bacteria
survive much better in OmCI-treated blood than untreated
blood, however phagocytosis is unchanged. To confirm that
our model works, and to highlight the difference between
Gram-negative M. catarrhalis and a Gram-positive bacteria, we
performed the same experiments in parallel with S. aureus.
As expected, inhibition of phagocytosis increased the survival
of S. aureus, while complement inhibition at the level of C5
did not (Figure 3C). Phagocytosis of S. aureus was similar to
M. catarrhalis, as it was unchanged by OmCI but inhibited by
cytochalasin D (Figure 3D). Altogether, this experiment confirms
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FIGURE 3 | In a whole blood model, M. catarrhalis is killed through MAC-mediated killing. CFSE-labeled bacteria were added to whole blood previously incubated
with 1 µM OmCI, 10 µM cytochalasin D or both. (A,B) M. catarrhalis clinical isolate #473 was picked as more serum resistant than most clinical isolates and the
reference strain RH4 (C,D) Staphylococcus aureus JE2 was used as an example of MAC-resistant bacteria (A,C) Survival of bacteria overtime was assessed by
collecting a sample at t = 0, 30, 60, and 90 min post-infection, and plating bacteria on agar plates. The number of bacteria is represented as log of CFU/ml. (B,D)
Phagocytosis was assessed by detection of CFSE+ cells among granulocytes and monocytes from whole blood. At 1 and 2 h post-infection, a sample was
collected, red blood cells were lysed, cells were fixed and stained with anti-CD14, and cells were analyzed using flow cytometry. The percentage of CFSE+ cells was
measured in granulocytes and monocytes (gated using Side Scatter and CD14 staining). Mean (±SD) from four (A) or three (B–D) independent experiments are
shown. Statistical significance of differences was calculated using two-way ANOVA with Dunnett’s post-test; *p < 0.05; **p < 0.01; and ***p < 0.001.
in an environment containing both complement and phagocytes,
M. catarrhalis is killed through MAC-mediated lysis. Based on
this, the effect of the fusion proteins in killing M. catarrhalis will
be evaluated in serum alone.
Recruitment of FH and or C4BP to the bacterial surface
interferes with complement deposition and contributes to serum
resistance. Therefore, we tested the ability of FH6–7/IgG and
C4BP1–2/IgM to augment serum killing. Both fusion proteins,
when pre-incubated with M. catarrhalis at a final fusion protein
concentration of 50 µg/ml, resulted in a significant reduction in
bacterial survival (Figure 4A). C4BP1–2/IgM did not displace
serum C4BP (Figure 2C), but still bound bacteria in the presence
of serum (Figure 2D), and the hexavalent structure of the
C4BP1–2/IgM fusion protein would most likely be a potent
activator of the classical pathway of complement, explaining
the reduced bacterial survival compared to no protein serum
control. Regarding the enhanced FH6–7/IgG-dependent serum
killing, both displacement of FH from the bacterial surface and
Fc-mediated activation of the classical pathway were likely to have
contributed to enhanced killing.
When fusion proteins were added with bacteria and serum
simultaneously we observed a statistically significant decrease
in survival with FH6–7/IgG and C4BP1–2/IgM (Figures 4A,B).
However, the reduction is less apparent with C4BP1–2/IgM
compared to FH6–7/IgG, likely because the C4BP1–2/IgM fusion
protein does not prevent serum C4BP binding on the bacterial
surface. Finally, we confirm that FH6–7/IgG enhances serum
killing of strain RH4 in a dose-dependent fashion that requires
active complement (Figure 4C).
FH6–7/IgG Enhances C3b and MAC
Deposition
In order to understand how FH6–7/IgG increased serum
sensitivity of M. catarrhalis we examined the deposition of
complement components iC3b, C3d, and MAC in the presence
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FIGURE 4 | FH6-7/IgG and C4BP1-2/IgM increase serum killing of M. catarrhalis. (A) Bacteria were pre-incubated with PBS (control), 50 µg/ml of FH6-7/IgG or
50 µg/ml of C4BP1-2/IgM for 30 min before addition of 10% NHS. Bacteria were counted at t = 0 and t = 30 min post-addition of serum and survival percentage
was calculated. (B) Fusion proteins and serum were added simultaneously to the bacteria, and bacteria survival was calculated. (C) Increasing amounts of
FH6-7/IgG were added simultaneously with NHS to bacteria and survival was calculated. Heat-inactivated NHS was used as a negative control of bacteria killing.
Mean (±SD) from three (A,C) or four (B) independent experiments are shown. Statistical significance of differences was calculated using one-way ANOVA with
Dunnett’s post-test; *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001.
and absence of fusion protein using flow cytometry. We
choose to investigate both iC3b and C3d as markers of C3b
deposition due to our previous experience with non-specific
binding and anomalies with Ab detection of cleaved complement
components. In accordance with the serum bactericidal data,
the presence of FH6–7/IgG resulted in a significant increase in
iC3b, C3d, and MAC deposition compared to no FH6–7/IgG
control (Figures 5A–C). In contrast, no significant differences
in complement deposition were observed when C4BP1–2/IgM
was simultaneously added with serum, likely because this assay is
not sensitive enough to detect a smaller increase in complement
deposition (Figures 5D–F). However, an increase in complement
deposition is observed when bacteria were pre-treated with
C4BP1–2/IgM, in accordance with the increase in serum killing
(Figures 5G–I).
FH6–7/IgG Binds a Broad Panel of
M. catarrhalis Clinical Isolates Resulting
in Enhanced Serum Killing
To ascertain whether FH6–7/IgG could be used as a novel
immunotherapeutic we investigated the activity of this fusion
protein against a panel of genetically diverse clinical isolates
of M. catarrhalis. These isolates represent a broad diversity of
virulent M. catarrhalis strains, and several UspA types: UspA2H
(like RH4), UspA2 NTER2A or NTER2B. Both fusion proteins
bind RH4 through the adhesin UspA2 (Figures 1E,F), therefore
it is of interest to know whether different UspA2 types can also
bind FH6–7/IgG and C4BP1–2/IgM. All M. catarrhalis clinical
isolates bound FH6–7/IgG, similarly to our lab strain RH4,
regardless of their UspA type (Figure 6A). This binding of FH6–
7/IgG fusion protein correlated with increased serum killing of
a majority of the M. catarrhalis clinical isolates independently
of their UspA type, when fusion protein and serum were added
simultaneously (Figures 6B–D). This shows that FH6–7/IgG
could constitute a promising therapeutic strategy in a large
number of M. catarrhalis infections.
C4BP1–2/IgM Binds a Broad Panel of
M. catarrhalis Clinical Isolates Resulting
in Enhanced Serum Killing
Similarly, we next investigated the activity of C4BP1–2/IgM
against a collection of genetically diverse M. catarrhalis clinical
isolates. Surprisingly, all clinical isolates bound C4BP1–2/IgM
much less than our reference strain RH4 (Figure 7A). To test
whether this lower binding could be due to the fact that these
isolates bind C4BP less than RH4, we assessed the binding
of C4BP from serum to these isolates. With the exception of
KR510, we observed significant correlation between the binding
of C4BP1–2/IgM and C4BP from serum (Figure 7B). In addition
all clinical isolates bound C4BP less than the laboratory strain
RH4 (Figure 7B). Although KR510 bound the fusion protein
poorly, it bound C4BP very strongly, suggesting that it may
bind C4BP through domains other than CCP1 and 2, the
only C4BP domains present in the fusion protein. Based on
the following observations; (1) C4BP1–2/IgM cannot prevent
the binding of C4BP from serum; (2) M. catarrhalis clinical
isolates bound C4BP1–2/IgM more poorly than RH4; and
(3) C4BP1–2/IgM was less efficient at enhancing RH4 serum
killing when simultaneously added (Figure 4B); we investigated
serum survival of clinical isolates pre-treated with C4BP1–2/IgM.
Although clinical isolates bound C4BP1–2/IgM more poorly
than RH4, we observed an increased killing of the majority of
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FIGURE 5 | Fusion proteins increase complement deposition on the bacterial surface. Flow cytometry was used to measure C3d, iC3b, and MAC binding at the
surface of M. catarrhalis. (A–C) FH6-7/IgG and serum were added simultaneously to bacteria. Bacteria were incubated with 5% OmCI-treated serum for 30 min for
C3 deposition, or 10% NHS for 20 min for MAC deposition. Heat-inactivated serum was used as a negative control of complement activation. (D–F) C4BP1-2/IgM
and serum were added simultaneously to bacteria. (G–I) Bacteria were pre-incubated with C4BP1-2/IgM before addition of serum. Mean (±SD) from three (A–F) or
four (G–I) independent experiments are shown. Statistical significance of differences was calculated using one-way ANOVA with Dunnett’s post-test; *p < 0.05;
**p < 0.01.
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FIGURE 6 | FH6-7/IgG binds to and increases serum killing of a large majority of M. catarrhalis clinical isolates. (A) 21 clinical isolates and the laboratory strain RH4
were tested for FH6-7/IgG binding by flow cytometry. In the absence of FH6-7/IgG, bacteria incubated with detection antibody had a similar gMFI for all isolates
(average 151, standard deviation 45). (B–D) Twelve clinical isolates were treated with 50 µg/ml of FH6-7/IgG or PBS, at the same time as 15% NHS, and their
survival after 30 min was assessed by plating bacteria and counting remaining colony forming-units (CFU). The remaining nine isolates were not included because
their survival in serum in the absence of fusion protein was less than 5%. (B) UspA2 NTER2A strains, (C) UspA2 NTER2B strains, (D) UspA2H strains. Mean (±SD)
from three (A–C) or four (D) independent experiments are shown. Statistical significance of differences was calculated using two-way ANOVA with Holm–Sidak’s
post-test; *p < 0.05; **p < 0.01; ***p < 0.001.
Frontiers in Immunology | www.frontiersin.org 10 September 2020 | Volume 11 | Article 2122
fimmu-11-02122 August 30, 2020 Time: 10:11 # 11
Laabei et al. Fusion Proteins Enhance Moraxella Killing
FIGURE 7 | C4BP1-2/IgM binds to and increases serum killing of many of the M. catarrhalis clinical isolates tested. (A) 21 clinical isolates and the lab strain RH4
were tested for C4BP1-2/IgM binding by flow cytometry. The gMFI for control without C4BP1-2/IgM was similar in all isolates (average 152, SD 75). (B) Clinical
isolates were tested for C4BP binding from NHS by flow cytometry. Moraxella isolates were treated with 5% NHS + OmCI for 30 min. The gMFI for control without
NHS was similar in all isolates (average 207, SD 132). (C–E) Twelve clinical isolates were treated with 50 µg/ml of C4BP1-2/IgM or PBS, before addition of as 15%
NHS, and their survival after 30 min was assessed by plating bacteria and counting remaining CFU. The remaining nine isolates were not included because their
survival in serum in the absence of fusion protein was less than 5%. (C) UspA2 NTER2A strains, (D) UspA2 NTER2B strains, (E) UspA2H strains. Mean (±SD) from
three (A) or four (B–E) independent experiments are shown. Statistical significance of differences was calculated using two-way ANOVA with Holm–Sidak’s
post-test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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M. catarrhalis isolates when they were pretreated with C4BP1–
2/IgM (Figures 7C–E).
DISCUSSION
The common respiratory pathogen M. catarrhalis causes
significant morbidity and economic burden because it is
responsible for otitis media in children and exacerbations of
chronic obstructive pulmonary disease in older individuals (2,
3). Currently, there is no vaccine to prevent M. catarrhalis
infection. Given that otitis media is the most common
reason for which children receive antibiotics (35), treatment
of M. catarrhalis disease with antibiotics promotes antibiotic
resistance and also disrupts normal commensal microbiota (1).
Therefore, the development of novel adjunctive anti-infective
immunotherapeutics against opportunistic pathogens such as
M. catarrhalis would be highly beneficial.
Complement is present and active in both anatomical regions
in which M. catarrhalis causes disease. In the ear, complement
cleavage activation fragments of C3, C4, and Factor B have been
detected in patients with otitis media with effusions (36). In a
separate study, the cytolytic activity and presence of the MAC
was observed in middle ear effusions obtained from persistent
otitis media infections (37). In addition, C3-coated bacteria were
identified in a small number of middle ear exudates originating
from children suffering from acute otitis media (38). The role
of complement in preventing middle ear infection has been
demonstrated. Complement depletion by use of cobra venom
factor restored the capacity of two avirulent NTHi strains to
cause otitis media in a chinchilla model of infection (39). In
the lungs, local synthesis of complement occurs; pulmonary
alveolar type II epithelial cells secrete complement proteins
C2, C4, C5, and Factor B (40), while bronchiolar epithelial
cells generate C3 and membrane bound complement regulatory
proteins (41). Complement components have been detected in
bronchial secretions isolated from guinea pigs. Importantly,
enhanced titers of complement proteins were observed following
intranasal infection of guinea pigs with mycoplasma, indicating a
role for complement in tackling lung infections (42). Moreover,
intranasal administration of FH6–7/IgG enhanced clearing of
NTHi in a mouse model of lung infection highlighting the
therapeutic potential of this fusion protein (20).
In this study, we showed that fusion proteins, FH6–7/IgG and
C4BP1–2/IgM, constitute novel antimicrobial strategies effective
in eliminating M. catarrhalis. In particular, FH6–7/IgG bound
all tested M. catarrhalis clinical strains taken from a cohort of
genetically diverse isolates. Importantly, FH6–7/IgG significantly
increased serum killing of the vast majority of tested isolates. Our
data suggests that enhanced killing was due to a combination
of (i) preventing the recruitment of the soluble complement
inhibitor FH to the bacterial surface via displacement, while (ii)
simultaneously promoting complement deposition by activation
of the classical pathway via the exposed IgG Fc region.
Incubation of M. catarrhalis with C4BP1–2/IgM also resulted
in decreased bacterial survival, although this was less efficient
than FH6–7/IgG when added simultaneously with NHS. This
is most likely due to the inability of C4BP1–2/IgM to out-
compete and displace C4BP recruited from serum. We showed
that C4BP1–2/IgM interacts with M. catarrhalis through UspA2,
similarly to C4BP and FH. C4BP is a large glycoprotein
containing seven identical alpha chains housing CCP domains,
which are integral for complement inhibition (43). Previous work
has illustrated that the binding region responsible for UspA2-
C4BP interaction is localized to the CCP2, CCP5, and CCP7
domains of the alpha chain (24). We show that M. catarrhalis
has the capacity to concomitantly bind C4BP and C4BP1–
2/IgM. As a result, bound C4BP can continue to inhibit
complement activation in the presence of C4BP1–2/IgM, thus
preventing significant bacterial killing. Our results suggest that
the bactericidal activity of C4BP1–2/IgM depends on which
factor, C4BP1–2/IgM or serum derived C4BP, interacts first with
the pathogen in vivo, as pre-incubation of the bacterium with
C4BP1–2/IgM significantly accelerates serum killing.
Importantly, previous work has shown using ex vivo assay and
in vivo animal models that these fusion proteins do not cause
unwanted complement activation or tissue damage. Bettoni et al.
(19) confirmed that C4BP1–2/IgM does not deposit complement
on human erythrocytes or apoptotic cells. Importantly, this
fusion protein lacks the CCP3 domain of C4BP which is
required for binding to C4b fragments on the cell surface and
therefore interaction of C4BP1–2/IgM with C4b-decorated cells
is prevented. Furthermore, the authors showed that C4BP1–
2/IgM was effective in preventing gonococcal colonization in
a mouse vaginal colonization model using human FH/C4BP
transgenic mice. Importantly, no adverse side effects following
administration of C4BP1–2/IgM to mice was observed over the
duration of the experiment. Blom et al. (22) confirmed that FH6–
7/IgG does not enhance classical or AP activation measured
via sensitized sheep and rabbit erythrocyte hemolysis assays.
In addition, using a platelet aggregation assay, FH6–7/IgG did
not activate platelets and no degree of coagulation activation
was observed. In addition, FH6–7/IgG was effective in reducing
mortality in a streptococcal sepsis model of infection using
human FH/C4BP transgenic mice and showed no adverse side
effects following administration. Specifically the authors noted no
enhanced complement deposition in tissues sections taken from
the eyes and kidneys of FH6-7/IgG treated and untreated animals,
either infected or not with S. pyogenes (22). Lastly, Shaughnessy
et al. (44) also observed no short term renal (increases in
creatinine) or hematologic (increases in lactate dehydrogenase or
decrease in hematocrit) or adverse side effects following systemic
administration of FH6–7/IgG. Although this data is encouraging,
future toxicology assessments are required and will take place
during the preclinical development of these fusion proteins.
Alternative treatments such as fusion proteins could reduce
the use of antibiotics, which are associated with many adverse
effects such as the development of antibiotic resistance and the
destruction of normal respiratory tract microbiota. Importantly,
developing new treatment approaches based on components used
by bacteria to confer serum resistance will ease or eliminate
the selective pressure required to drive resistance against these
therapeutics. We show that binding of both fusion proteins
(FH6–7/IgG and C4BP1–2/IgM) to M. catarrhalis relies heavily
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on the expression of Usp proteins, particularly UspA2. UspA2
is a non-fimbrial surface protein (45), highly conserved across
disease isolates (46) and expressed during in vivo infection
(47). Resistance to fusion proteins would require the emergence
of UspA2 null mutants or UspA2 mutants unable to interact
with FH6–7 and/or C4BP1–2 domains of circulating FH and
C4BP, respectively, resulting in the reduced ability to recruit
these soluble regulators. UspA2 plays even more roles in
complement evasion as in addition to FH and C4BP, it also
binds vitronectin, a multifunctional glycoprotein which can
prevent the formation of MAC on the bacterial surface (32),
and plasminogen, a zymogen which when converted to plasmin
can degrade central complement components (33). Interaction of
UspA2 with these glycoproteins adds extra pressure to maintain
the WT UspA2 protein sequence and/or conformation. An
inability to bind C4BP, FH, vitronectin and plasminogen due
to loss of UspA2 would pose a significant fitness disadvantage
promoting eradication by complement activity (24, 32, 48, 49).
Moraxella catarrhalis is both a normal commensal and a
pathogen of the respiratory tract (50), and although little is
known about the differences between the two or how it switches
from one to the other, preserving the healthy microbiota when
targeting pathogenic bacteria is critical. Microbial community
composition has a profound impact on human health, protecting
against the growth and invasion of respiratory pathogens
(51), helping with the development and maintenance of a
healthy immune system (52), but also preventing neurological
diseases such as Parkinson’s disease, Alzheimer’s disease, and
multiple sclerosis (53). M. catarrhalis strains isolated from
patients with bronchopulmonary infection were more resistant
to complement-mediated killing than strains harbored by healthy
carriers (89% vs 41.5%) (54). Furthermore, clinical studies have
revealed that the increased prevalence of M. catarrhalis infections
in the winter is due to the exposure to reduced environmental
temperature in the nasopharynx (cold shock response), which
increases the expression of virulence factors, including UspA2
(55). Cold-shocked bacteria therefore can bind more C4BP
and FH through UspA2 and have an increased resistance to
complement. Targeting strains that are able to bind complement
inhibitors may thereby select between pathogenic strains and
strains part of healthy microbiota.
The development of complement-activating antibodies
targeting bacteria represents a promising strategy for
antibacterial therapies but is limited by the need to raise
specific antibodies against conserved, abundant surface proteins,
which are expressed during infection. Such ubiquitous protective
epitopes are very difficult to identify, because of the considerable
antigenic and phase variability between strains within a species.
Making monoclonal antibodies that recognize a wide array of
strains and are functional is therefore extremely challenging.
The fusion proteins outlined in this study bypass this restriction
by behaving as soluble complement inhibitor decoys, which are
bound by the majority of clinical isolates. Noteworthy, binding
of complement inhibitors is an evasion strategy developed by
many different pathogens, from fungi such as Aspergillus spp.
and Candida albicans (56–58), parasites such as Plasmodium
falciparum (59), and many bacterial species. Among these
bacteria, FH6–7/IgG fusion protein successfully enhanced the
killing of H. influenzae (20), N. meningitidis (18), N. gonorrhoeae
(21), and Streptococcus pyogenes (22), while C4BP1–2/IgM
strongly enhanced the killing of N. gonorrhoeae (19). Therefore,
fusion proteins can prove very useful in the treatment of
large variety of infections with this study highlighting their
effectiveness in enhancing serum killing of M. catarrhalis.
CONCLUSION
In conclusion, we have shown that fusion proteins combining
bacteria-binding sequences of complement inhibitors and
Fc parts of immunoglobulins constitute a novel therapeutic
approach against the human pathogen M. catarrhalis. Targeting
such a key immune evasion strategy evolved by bacteria allows
us to treat infection without triggering antibiotics resistance, and
can be extended to a large variety of human pathogens.
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